Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nge Act of 1934, as amended, the complete text of Item 5.02 of the Original Form 8‑K, as amended hereby, is set forth be |
Stammdaten
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Allogene Therapeutics, Inc. |
|---|---|
| Ticker | ALLO |
| CIK | 0001737287 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 537,7 Mio. USD |
| Beta | 0,54 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -190,886,000 | -0.87 | 415,905,000 | 292,542,000 |
| 2025-09-30 | 10-Q | 0 | -41,400,000 | -0.19 | 439,771,000 | 315,329,000 |
| 2025-06-30 | 10-Q | 0 | -50,943,000 | -0.23 | 470,593,000 | 344,561,000 |
| 2025-03-31 | 10-Q | 0 | -59,733,000 | -0.28 | 507,982,000 | 385,393,000 |
| 2024-12-31 | 10-K | 22,000 | -257,590,000 | -1.32 | 548,710,000 | 422,179,000 |
| 2024-09-30 | 10-Q | 0 | -66,293,000 | -0.32 | 589,120,000 | 463,748,000 |
| 2024-06-30 | 10-Q | 0 | -66,358,000 | -0.35 | 646,883,000 | 515,038,000 |
| 2024-03-31 | 10-Q | 22,000 | -65,000,000 | -0.38 | 586,350,000 | 461,367,000 |
| 2023-12-31 | 10-K | 95,000 | -327,265,000 | -2.09 | 642,837,000 | 512,233,000 |
| 2023-09-30 | 10-K | 22,000 | -62,287,000 | -0.37 | 713,411,000 | 580,635,000 |
| 2023-09-30 | 10-Q | 22,000 | -62,287,000 | -0.37 | 712,326,000 | 580,635,000 |
| 2023-06-30 | 10-Q | 22,000 | -79,232,000 | -0.54 | 770,971,000 | 621,411,000 |
| 2023-06-30 | 10-K | 22,000 | -79,232,000 | -0.54 | 773,007,000 | 621,411,000 |
| 2023-03-31 | 10-Q | 30,000 | -99,968,000 | -0.69 | 746,871,000 | 592,010,000 |
| 2023-03-31 | 10-K | 30,000 | -99,968,000 | -0.69 | 750,128,000 | 592,010,000 |
| 2022-12-31 | 10-K | 156,000 | -340,414,000 | -2.38 | 821,579,000 | 666,882,000 |
| 2022-09-30 | 10-Q | 49,000 | -83,148,000 | -0.58 | 887,572,000 | 739,961,000 |
| 2022-09-30 | 10-K | 27,000 | -84,242,000 | -0.59 | 894,477,000 | 743,401,000 |
| 2022-06-30 | 10-K | 64,000 | -80,290,000 | -0.56 | 955,621,000 | 806,483,000 |
| 2022-06-30 | 10-Q | 86,000 | -74,787,000 | -0.52 | 947,644,000 | 801,949,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Chang David D | Director, Officer, President and CEO | Open Market Sale | -47,763 | 2.47 | -117,974.61 | -244,8% | |
| 2026-03-16 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -4,835 | 2.47 | -11,942.45 | -24,8% | |
| 2026-03-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,132 | 2.60 | -18,543.20 | -38,5% | |
| 2026-02-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,549 | 1.73 | -13,059.77 | -27,1% | |
| 2026-02-02 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -24,001 | 1.76 | -42,241.76 | -87,7% | |
| 2026-02-02 | Yoshiyama Annie | Officer, SVP, Finance | Open Market Sale | -4,167 | 1.72 | -7,167.24 | -14,9% | |
| 2026-02-02 | Chang David D | Director, Officer, President and CEO | Open Market Sale | -95,269 | 1.80 | -171,484.20 | -355,9% | |
| 2026-02-02 | Douglas Earl Martin | Officer, SVP, General Counsel | Open Market Sale | -22,900 | 1.76 | -40,304.00 | -83,6% | |
| 2026-02-02 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -35,700 | 1.77 | -63,189.00 | -131,1% | |
| 2026-01-21 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -26,269 | 1.56 | -40,979.64 | -85,0% | |
| 2025-11-17 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -786 | 1.22 | -958.92 | -2,0% | |
| 2025-10-21 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -36,744 | 1.26 | -46,168.84 | -95,8% | |
| 2025-06-10 | MESSEMER DEBORAH M. | Director | Open Market Sale | -36,885 | 1.42 | -52,376.70 | -108,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.